Acer therapeutics regains compliance with nasdaq listing standard

Newton, mass., march 31, 2022 (globe newswire) -- acer therapeutics inc. (nasdaq: acer), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that it has received notice from the nasdaq stock market (nasdaq) on march 30, 2022 informing acer that it has regained compliance with the minimum market value of listed securities standard under nasdaq listing rule 5550(b)(2) for continued listing on the nasdaq capital market, and the matter is now closed.
ACER Ratings Summary
ACER Quant Ranking